|
Entire cohort
| |
Women
| |
Men
| |
---|
HR (95% CI)
|
n(events)
|
HR (95% CI)
|
n(events)
|
HR (95% CI)
|
n(events)
|
---|
KRAS status (unadjusted)
| | | | | | |
Wild-type
|
1.00
|
334 (113)
|
1.00
|
177 (52)
|
1.00
|
157 (61)
|
Codon 12-mutated
|
1.05 (0.76–1.45)
|
156 (54)
|
1.32 (0.85–2.05)
|
83 (32)
|
0.81 (0.50–1.32)
|
73 (22)
|
Codon 13-mutated
|
1.94 (1.18–3.19)
|
34 (18)
|
2.58 (1.31–5.09)
|
18 (10)
|
1.42 (0.68–2.96)
|
16 (8)
|
KRAS status (adjusted)
| | | | | | |
Wild-type
|
1.00
|
273 (87)
|
1.00
|
146 (39)
|
1.00
|
127 (65)
|
Codon 12-mutated
|
1.02 (0.69–1.51)
|
132 (44)
|
1.29 (0.75–2.22)
|
67 (24)
|
0.74 (0.42–1.30)
|
65 (20)
|
Codon 13-mutated
|
1.37 (0.74–2.54)
|
28 (13)
|
1.83 (0.79–4.23)
|
15 (7)
|
0.87 (0.34–2.72)
|
13 (6)
|
BRAF status (unadjusted)
| | | | | | |
Wild-type
|
1.00
|
446 (154)
|
1.00
|
227 (75)
|
1.00
|
219 (79)
|
Mutated
|
1.32 (0.90–1.94)
|
78 (32)
|
1.23 (0.74–2.04)
|
50 (19)
|
1.56 (0.87–2.81)
|
28 (13)
|
BRAF status (adjusted)
| | | | | | |
Wild-type
|
1.00
|
370 (122)
|
1.00
|
184 (56)
|
1.00
|
186 (66)
|
Mutated
|
1.56 (0.87–2.79)
|
63 (22)
|
1.47 ( 0.65–3.33)
|
44 (14)
|
3.50 (1.41–8.70)
|
19 (8)
|
- Adjusted analysis included age (continuous), sex, T stage (I-II, III, IV), N stage (0, 1, 2), M stage (0, 1), differentiation grade (high-intermediate vs. low and vascular invasion (+/−/unknown)), KRAS mutation status (wild-type, codon 12 mutation, codon 13 mutation) and BRAF mutation status (wild-type, mutated). One case with mutual KRAS codons 12 and 13 mutation was excluded from the analyses related to KRAS mutational status.